Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON

By sjmartinez • May 8, 2025

Peters S, Oliner KS, L'Hernault A, Ratcliffe M, Madison H, Lai Z, Stewart R, Mann H, Lowery C, Garon EB, Mok T, Johnson ML. Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON. ESMO Open. 2025 May 6;10(5):105058. doi: 10.1016/j.esmoop.2025.105058. Epub ahead of print. PMID: 40334315.

Tags: durvalumab, Hematology/Oncology, non-small-cell lung cancer, POSEIDON, Publications, tremelimumab, tumor mutational burden

PAK4 orchestrates dual transcriptional and post-translational repression of E-cadherin to promote epithelial-to-mesenchymal transition and invasiveness in pancreatic cancer

Kim KJ, Lee CH, Nam M, Na HY, Sung JH, Park BR, Hwang SH, Park W, Seo J, Kang M, Jung EH, Kim SA, Suh[...]

Discussing lung cancer management options in the emergency department

Moghanaki D, Goldman J, Weingrow D, Hendey GW. Discussing lung cancer management options in the emergency department. Emerg Med J. 2026 Oct 30:emermed-2026-216560. doi: 10.1136/emermed-2026-216560.[...]

p53 activation via pharmacologic MDM2 inhibition constrains exhaustion and enhances antitumor function of human CD8+ T cells

Boix de Jesus A, Dao HB, Imani A, Rodriguez GA, Shehata MS, Chandran RR, Fine SA, Lim SY, To M, Lofftus SY, Pedroncelli N, Eilber[...]